59 - References

References

Bipolar disorder CHAPTER 2 References

1. Malhi GS, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders: bipolar disorder summary. Bipolar Disord 2020; 22:805–­821.
2. Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97–­170.
3. Kang MG, et al. Lithium vs valproate in the maintenance treatment of bipolar I disorder: a post-hoc analysis of a randomized double-­blind placebo-­controlled trial. Aust NZ J Psychiatry 2020; 54:298–­307.
4. Solomon DA, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry 2010; 67:339–­347.
5. Perlis RH, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-­BD). Am J Psychiatry 2006; 163:217–­224.
6. Goodwin GM, et  al. Evidence-­based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495–­553.
7. Nestsiarovich A, et al. Preventing new episodes of bipolar disorder in adults: systematic review and meta-­analysis of randomized controlled trials. Eur Neuropsychopharmacol 2022; 54:75–­89.
8. Sani G, et al. Treatment of bipolar disorder in a lifetime perspective: is lithium still the best choice? Clin Drug Investig 2017; 37:713–­727.
9. Hartong EG, et  al. Prophylactic efficacy of lithium versus carbamazepine in treatment-­naive bipolar patients. J Clin Psychiatry 2003; 64:144–­151.
10. Cipriani A, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013; 10:CD003196.
11. Geddes JR, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-­label trial. Lancet 2010; 375:385–­395.
12. Kemp DE, et al. A 6-­month, double-­blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-­cycling bipolar disorder and co-­occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113–­121.
13. Smith LA, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394–­412.
14. Cipriani A, et al. Lithium in the prevention of suicidal behavior and all-­cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162:1805–­1819.
15. Kessing LV, et al. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62:860–­866.
16. Song J, et al. Suicidal behavior during lithium and valproate treatment: a within-­individual 8-­year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry 2017; 174:795–­802.
17. Mander AJ, et al. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; 2:15–­17.
18. Faedda GL, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50:448–­455.
19. Macritchie KA, et al. Does ‘rebound mania’ occur after stopping carbamazepine? A pilot study. J Psychopharmacol 2000; 14:266–­268.
20. Franks MA, et al. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. J Psychopharmacol 2008; 22:452–­456.
21. Kessing LV, et al. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 2014; 205:214–­220.
22. Kessing LV, et al. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-­based cohort study. Br J Psychiatry 2011; 199:57–­63.
23. Gao K, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005; 66:1376–­1385.
24. Hellewell JS. A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. J Psychopharmacol 2006; 20:39–­45.
25. Gigante AD, et al. Long-­acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012; 26:403–­420.
26. Tohen M, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-­week study. Am J Psychiatry 2003; 160:1263–­1271.
27. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed October 2024); https://www.nice.org.uk/guidance/cg185.
28. Vieta E, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109:251–­263.
29. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: a review. Clin Ther 2010; 32 Suppl 1:S32–­S38.
30. Ghaemi SN, et al. Long-­term risperidone treatment in bipolar disorder: 6-­month follow up. Int Clin Psychopharmacol 1997; 12:333–­338.
31. Szegedi A, et al. Randomized, double-­blind, placebo-­controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2017; 175:71–­79.
32. Bowden CL, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-­week trial. Int Clin Psychopharmacol 2010; 25:60–­67.
33. Calabrese JR, et  al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017; 27:865–­876.
34. McIntyre RS, et  al. The efficacy of lumateperone in patients with bipolar depression with mixed features. J Clin Psychiatry 2023; 84:22m14739.
35. McIntyre RS, et al. Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. Bipolar Disord 2024; 26:442–­453.
36. Kishi T, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-­ analysis of randomized controlled trials. Mol Psychiatry 2021; 26:4146–­4157.
37. Escudero MAG, et al. Second generation antipsychotics monotherapy as maintenance treatment for bipolar disorder: a systematic review of long-­term studies. Psychiatr Q 2020; 91:1047–­1060.

330 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2 38. Calabrese JR, et al. Efficacy and safety of aripiprazole once-­monthly in the maintenance treatment of bipolar I disorder: a double-­blind, placebo-­controlled, 52-­week randomized withdrawal study. J Clin Psychiatry 2017; 78:324–­331. 39. Kishi T, et al. Long-­acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-­analyses of randomized controlled trials. Int J Neuropsychopharmacol 2016; 19:pyw038. 40. Hsieh MH, et al. Bipolar patients treated with long-­acting injectable risperidone in Taiwan: a 1-­year mirror-­image study using a national claims database. J Affect Disord 2017; 218:327–­334. 41. Belge JB, et al. Long-­acting second-­generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review. Expert Opin Pharmacother 2024; 25:295–­299. 42. Kishi T, et al. A comparison of recurrence rates after discontinuation of second-­generation antipsychotic long-­acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: a systematic review. Psychiatry Res 2024; 333:115761. 43. Pacchiarotti I, et al. Long-­acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol 2019; 29:457–­470. 44. Yıldızhan E, et al. Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder –­ a naturalistic mirror image study. Nord J Psychiatry 2022; 76:37–­43. 45. Nolen WA, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. Bipolar Disord 2019; 21:394–­409. 46. Freeman MP, et al. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155:12–­21. 47. Muzina DJ, et  al. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust NZ J Psychiatry 2005; 39:652–­661. 48. Tohen M, et al. Relapse prevention in bipolar I disorder: 18-­month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184:337–­345. 49. Paton C, et al. Lithium in bipolar and other affective disorders: prescribing practice in the UK. J Psychopharmacol 2010; 24:1739–­1746. 50. Marcus R, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-­term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-­blind, randomized study. Bipolar Disord 2011; 13:133–­144. 51. Bowden CL, et al. A placebo-­controlled 18-­month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60:392–­400. 52. Pikalov A, et al. Long-­term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. Int J Bipolar Disord 2017; 5:9. 53. Wingård L, et al. Monotherapy vs. combination therapy for post mania maintenance treatment: a population based cohort study. Eur Neuropsychopharmacol 2019; 29:691–­700. 54. Jauhar S, et al. Controversies in bipolar disorder; role of second-­generation antipsychotic for maintenance therapy. Int J Bipolar Disord 2019; 7:10. 55. Ghaemi SN, et al. Long-­term antidepressant treatment in bipolar disorder: meta-­analyses of benefits and risks. Acta Psychiatr Scand 2008; 118:347–­356. 56. Ghaemi SN, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-­BD) randomized clinical trial of long-­term effectiveness and safety. J Clin Psychiatry 2010; 71:372–­380. 57. Yatham LN, et al. Duration of adjunctive antidepressant maintenance in bipolar I depression. N Engl J Med 2023; 389:430–­440.